The fact
This deal targets treatments for rare and resistant cancers.
The French group confirms its external growth strategy in biotechnology.
Click the link to read an article on the topic:
This deal targets treatments for rare and resistant cancers.
The French group confirms its external growth strategy in biotechnology.